why choose us

First received: March 24, 2023

Clinical Trial: Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States

Study Status: Completed

Recruit Status: RECRUITING

Condition: Cirrhosis

Study Type: INTERVENTIONAL


Official Title: Liver Cirrhosis Network (LCN) Rosuvastatin Efficacy and Safety for Cirrhosis in the United States (RESCU): A Double-Blind Randomized, Placebo-Controlled Phase 2 Study

Brief Summary: This is a double-blind, phase 2 study to evaluate safety and efficacy of rosuvastatin in comparison to placebo after 2 years in patients with compensated cirrhosis.

Read more